🔒 Time for Wegovy to treat more than just obesity: Lisa Jarvis
Novo Nordisk's Wegovy emerges as more than just an obesity treatment—it's a potential game-changer for heart health.
Stay updated with breaking news from James Januzzi. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Novo Nordisk's Wegovy emerges as more than just an obesity treatment—it's a potential game-changer for heart health.
Subanalysis finds benefit for patients not on heart-beneficial antidiabetic medication
Empagliflozin did not significantly reduce overall HF hospitalization or all-cause death in high-risk patients in EMPACT-MI but did reduce first and total hospitalizations.
Trial missed primary endpoint but suggestive results support more diuresis with less diuretic use
This 2024 American Heart Month 2024 feature paints a picture describing the current state of cardiology by asking what the most prevalent and important issues facing the specialty are today from the perspective of 9 leading experts.